Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GMRS · against 1,336 other Healthcare companies
Ranked #222 of 1,337 · scores higher than 83% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 80–89, including GMRS · Click a bar to see the companies
Mainly thanks to its EBITDA yield, which is stronger than most Healthcare peers.
| Metric | GMRS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | -17.8% | 1.5% | 13% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 20.2% | 4.2% | 95% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | Not reported | -1.0% | — | — | 20% |
| Book yieldHigher is better · 1,306 reported | 89.2% | 37.9% | 83% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 222 | 1.4B USD | 83 | 73 | |
| 222 | 126.1B USD | 83 | 62 | |
| 222 | 748M USD | 83 | 62 | |
| 222 | 540.4B BRL (≈$97.3B) | 83 | 64 | |
| 222 | 615M USD | 83 | 48 | |
| 222 | 13.8B SEK (≈$1.4B) | 83 | 56 | |
| 222 | 360M USD | 83 | 67 | |
| 222 | 34.3B USD | 83 | 57 | |
| 235 | 26.6B CNY (≈$3.7B) | 82 | 67 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score